RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Gilead Sciences (GILD) and lowers the price target from $76 to $74.
April 26, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Gilead Sciences but lowered the price target from $76 to $74.
The reduction in price target by RBC Capital suggests a slightly less optimistic outlook on Gilead Sciences' stock performance in the short term. This adjustment could lead to a negative perception among investors, potentially causing a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100